Abstracts tagged "Disease Activity"

Abstract Number: 381 • 2018 ACR/ARHP Annual Meeting
Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
David Amici^1,2, Iago Pinal-Fernandez^3,4, Ruben Pagkatipunan⁵, Albert Mears⁵, Rebecca De Lorenzo⁶, Eleni Tiniakou⁷, Jemima Albayda³, Julie J. Paik⁷, Thomas E. Lloyd⁸, Lisa Christopher-Stine⁹, Andrew Mammen^8,10 and Tae Chung¹¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ¹⁰National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹¹Johns Hopkins University, Baltimore, MD
Background/Purpose: To assess muscle function in myositis patients, clinicians typically use manual muscle testing (MMT), a measure of maximal isometric strength. However, patients with high…
Abstract Number: 637 • 2018 ACR/ARHP Annual Meeting
How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Laura C. Coates², Ana-Maria Orbai³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder¹⁵, Inna Gaydukova¹⁶, Ennio Lubrano¹⁷, Pascal Richette¹⁸, M. Elaine Husni¹⁹, Maarten de Wit²⁰, Josef S. Smolen²¹ and Laure Gossec²², ¹Sorbonne Université, PARIS, France, ²University of Oxford, Oxford, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁷Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁸Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁹Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²⁰Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²²Sorbonne Universités, Paris, France
Background/Purpose: Remission (REM) or minimal/low disease activity (LDA) is the treatment goal in Psoriatic Arthritis (PsA). There is no consensus on definitions of REM/LDA. Recently,…
Abstract Number: 1462 • 2018 ACR/ARHP Annual Meeting
Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness
Dana Orange¹, Caroline Jiang¹, Edward F. DiCarlo², Tania Pannellini³, Laura T. Donlin⁴, Serene Z. Mirza⁵, Mark P. Figgie⁶, Vivian P. Bykerk⁷, Ana-Maria Orbai⁸, Sarah Mackie⁹ and Susan M. Goodman³, ¹Rockefeller University, New York, NY, ²Laboratory Medicine, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Surgery, Hospital for Special Surgery, New York, NY, ⁷Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom
Background/Purpose: Stiffness is a hallmark of RA, but little is known about the etiology. We investigated stiffness association with RA disease activity and determined whether…
Abstract Number: 1675 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Meenakshi Jolly¹, Hervé Devilliers², Iñigo Rúa-Figueroa³, Desiree R Azizoddin⁴, Raúl Menor Almagro⁵, Francisco Javier López Longo⁶, Juan Gabriel Ovalles-Bonilla⁷, Alejandro Olivé-Marques⁸, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernandez-Nebro¹⁰, Jaime Calvo-Alen¹¹, Txaro García de Vicuña-Pinedo¹², Eva G Tomero-Muriel¹³, Esther Uriarte Isacelaya¹⁴, Angela Pecondon-Español¹⁵, Mercedes Freire-González¹⁶, Ricardo Blanco¹⁷, Marian Gantes Mora¹⁸, Monica Ibanez Barcelo¹⁹, Carlos Alberto Montilla-Morales²⁰, José José C Rosas-Gómez de Salazar²¹, Jesús García-Villanueva²², Paloma Vela-Casasempere²³, María E Ruiz-Lucea²⁴, Francisco J Toyos-Sáenz-de-Miera²⁵, José Hernández Beiraín²⁶, Elvira Diez Alvarez²⁷, Gema Bonilla-Hernán²⁸, Javier Narváez-García²⁹, José Andréu-Sánchez³⁰, Mireia Moreno-Martínez-Losa³¹, Ana Sánchez Atrio³², Maria Loreto Horcada³³, Tatiana Cobo-Ibáñez³⁴, Carlos Marras Fernandez-Cid³⁵, Tomas Ramón Vazquez Rodriguez³⁶, Eva Salgado-Pérez³⁷, Vicente Torrente³⁸, Juan Alegre-Sancho³⁹, Coral Mouriño-Rodriguez⁴⁰, Joel A. Block¹ and JM Pego-Reigosa⁴¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²de médecine Interne, Hôpital Universitaire Dijon, Dijon, France, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez, Spain, ⁶Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ¹⁵Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹H. Son Llatzer, Palma de Mallorca, Spain, ²⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²²HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²³Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁴Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Complejo Asistencial Universitario de León, León, Spain, ²⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ³⁰HOSPITAL PUERTA DE HIERRO, Madrid, Spain, ³¹HOSPITAL PARC TAULÍ, Barcelona, Spain, ³²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³³Rheumatology, Hospital de Navarra, Pamplona, Spain, ³⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷COMPLEJO HOSPITALARIO DE OURENSE, Ourense, Spain, ³⁸Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁹HOSPITAL DR. PESET, València, Spain, ⁴⁰Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ⁴¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: Remission & Low Disease activity state (LDAS) are the two new health outcome measures developed with “treat to target” strategy in mind for Systemic…
Abstract Number: 2041 • 2018 ACR/ARHP Annual Meeting
Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis
Clémence Gorlier¹, Hafid Ait Oufella², Ludivine Laurans², Alexandra Rousseau³, Sophie Georgin-Lavialle⁴, Harry Sokol⁵, Francis Berenbaum¹, Simon Tabassome⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam¹, ¹AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ²Inserm U970, Paris Cardiovascular Research Center, Paris, France, ³AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB, Paris, France, ⁴AP-HP Tenon hospital, Sorbonne Université Paris, Paris, France, ⁵AP-HP Saint-Antoine hospital, Sorbonne Université Paris, France, Paris, France, ⁶AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB), Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France
Background/Purpose: Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a cell surface receptor expressed mainly on monocytes and neutrophils, known to amplify inflammatory response. We…
Abstract Number: 2489 • 2018 ACR/ARHP Annual Meeting
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Irini Genitsaridi^1,2, Irini Flouri³, Argyro Repa², Nestor Avgoustidis², Nikolaos Kougkas², Ioannis Papalopoulos², Styliani Polia², Konstantinos Marias¹, Dimitris Plexousakis⁴, George Bertsias² and Prodromos Sidiropoulos², ¹Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece, ²Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ³Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklio, Greece, ⁴Information Systems Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece
Background/Purpose: Registry data have shown that treatment with bDMARDs induces remission or LDA (RLDA) in up-to 50% of RA patients. Approximately 30-50% of patients have…
Abstract Number: 2835 • 2018 ACR/ARHP Annual Meeting
Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu¹, Ann Ranger², Normand Allaire², Patrick Cullen³ and Laurence S Magder⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Biogen Idec, Cambridge, MA, ³Biogen Idec, Cambridge, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We assessed the stability of BAFF, interferon, plasma cell and LDG neutrophil gene expression signatures over time, and whether changes in gene expression coincided…
Abstract Number: 386 • 2018 ACR/ARHP Annual Meeting
Differences in Body Composition in Myositis Patients and Healthy Controls Are Associated with Disease Activity and Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Sabina Oreska^1,2, Maja Spiritovic^1,3, Petr Cesak⁴, Ondrej Marecek⁵, Hana Storkanova^1,2, Hana Smucrova¹, Barbora Hermankova^1,3, Katerina Kubinova^1,2, Martin Klein^1,2, Lucia Vernerova^1,2, Olga Ruzickova^1,6, Karel Pavelka^1,2, Ladislav Šenolt^1,2, Herman F Mann^1,7, Jiri Vencovsky^1,8 and Michal Tomcik^1,2, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁵Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁷First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁸Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skeletal muscle, pulmonary and articular involvement in idiopathic inflammatory myopathies (IIM) limit the mobility/self-sufficiency of patients, and can have a negative impact on body…
Abstract Number: 822 • 2018 ACR/ARHP Annual Meeting
Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis
Andrea D. Gloor¹, Daniel Yerly², Jennifer L. Cullmann³, Sabine Adler¹ and Peter M. Villiger¹, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Department of Biomedical Research, University of Bern, Bern, Switzerland, ³Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital of Bern, Bern, Switzerland
Background/Purpose: There is an unmet need for tools to quantify local disease activity in TAK.Methods: Sera of 21 TAK patients, aged between 18 and 56…
Abstract Number: 1467 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics
Lucía González-Rodríguez¹, Valentina Calamia¹, Patricia Fernández², Cristina Ruiz-Romero³, Antonio Julià⁴, Antonio Fernández-Nebro⁵, Jesús Tornero⁶, Sara Marsal⁴ and Francisco J Blanco³, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ³Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Spain, ⁵UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Spain, ⁶Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting
Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage
Muhammad Mehmood Riaz^1,2, Liang SHEN³, Lay Kheng Teoh⁴, Rangi Kandane-Rathnayake⁵ and Aisha Lateef⁶, ¹Department of Medicine, National University Hospital, Singapore, Singapore, ²Department of Medicine, Aga Khan University, karachi, Pakistan, ³Biostatistics Unit, National University Health System, Singapore, Singapore, ⁴National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore, ⁵School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…
Abstract Number: 2086 • 2018 ACR/ARHP Annual Meeting
4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model
Yunjung Choi¹, Ji-hyun Jung², Eun-Kyeong Lee², Myeung Su Lee³, Changhoon Lee⁴ and Wan-Hee Yoo⁵, ¹Division of Rheumatology, Department of Internal Medicine, Research Institute of Clinical Medicine of chonbuk national university-Biomedical Research Institute of chonbuk national university hospital, jeonju, Korea, Republic of (South), ²Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea, Republic of (South), ³Department of Rheumatology, Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea, Republic of (South), ⁵Division of Rheumatology, Department of Internal Medicine, Research Institute of Clinical Medicine of chonbuk national university-Biomedical Research Institute of chonbuk national university hospital, Jeonju, Korea, Republic of (South)
Background/Purpose: The purpose of the present study was to investigate whether ER stress inhibition by 4-phenylbutyric acid (4-PBA) ameliorates lupus manifestations in an experimental lupus…
Abstract Number: 2491 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Jing Yang¹, Hua Wei², Jianlin Huang³, Wenqiang Fan⁴, Hongzhi Wang⁵, Yongfu Wang⁶, Rong Mu⁷, Chun Li⁸, Jinmei Zou¹, Yu Zhang¹, Bin Wu⁹, Jianling Dong¹, Xiaofei Shi¹⁰, Xinwang Duan¹¹, Jianhong Wu¹², Fang He¹³, Hong Liu¹, Zhijun Li¹⁴, Guosheng Wang¹⁵, Shengguang Li¹⁶, Bei Wang¹⁷, Yanjie Hao¹⁸, Huiqiong Zhou¹⁹, Haili shen²⁰, Yang Cui²¹, Wenhui Huang²², Qing-chun Huang²³, Hui Xiao²⁴, Yuhua Jia²⁴, Fei Xiao²⁴ and Feng-Chun Zhang²⁵, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵The First Hospital of Jiaxing, Jiaxing, China, ⁶The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁷Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁸Peking University People's Hospital, Beijing, China, ⁹Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹¹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹²Dazhou Central Hospital, Dazhou, China, ¹³Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁵Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹⁶Peking University International Hospital, Beijing, China, ¹⁷Beijing Hospital of Traditional Chinese Medicine (TCM), Beijing, China, ¹⁸The First Affiliated Hospital of Beijing University, Beijing, China, ¹⁹The First Affiliated Hospital of PLA General Hospital, Beijing, China, ²⁰Department of Rheumatology and Immunology, Second Hospital of Lanzhou University, lanzhou, China, ²¹Guangdong General Hospital, Guangzhou, China, ²²The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ²³Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: T2T, achieving a DAS28 score lower than 3.2 is the main management strategy recommended by ACR and EULAR. HAQ is the most widely used…
Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Huifeng Yun¹, Lang Chen¹, Fenglong Xie¹, Himanshu Patel², Natalie Boytsov², Xiang Zhang² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…
Abstract Number: 18 • 2018 ACR/ARHP Annual Meeting
Cytoplasmic FOXO1 Identifies Novel Disease-Activity Associated B Cell Subsets in SLE
Molly Hritzo¹ and Amit Golding², ¹Microbiology and Molecular Immunology, University of Maryland School of Medicine, Baltimore, MD, ²10 South Pine Street, Baltimore VA/VAMHCS AND University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A key integrator of external stimuli in lymphocytes, Forkhead box protein O1 (FOXO1) is a highly attractive factor to study in SLE because it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].